This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts initiated coverage on several companies with bullish ratings. Guggenheim initiated Twist Bioscience (TWST) with a Buy rating and a $53 price target. BMO Capital initiated Old Dominion Freight Line (ODFL) with an Outperform rating and a $210 price target. Cantor Fitzgerald initiated Proto Labs (PRLB) with an Overweight rating and a $44 price target. Goldman Sachs initiated Jazz Pharmaceuticals (JAZZ) with a Buy rating and a $169 price target. Craig-Hallum initiated Spire Global (SPIR) with a Buy rating and a $13 price target.
June 05, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs initiated coverage on Jazz Pharmaceuticals with a Buy rating and a $169 price target. Shares fell 1.2% to $104.48.
Despite the initial drop in share price, the Buy rating and high price target from Goldman Sachs are likely to positively impact JAZZ's stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
BMO Capital initiated coverage on Old Dominion Freight Line with an Outperform rating and a $210 price target. Shares rose 1.7% to $172.14.
The Outperform rating and high price target from BMO Capital are likely to positively influence ODFL's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Cantor Fitzgerald initiated coverage on Proto Labs with an Overweight rating and a $44 price target. Shares fell 0.2% to $30.32.
Despite the slight drop in share price, the Overweight rating and price target from Cantor Fitzgerald are likely to have a positive short-term impact on PRLB's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Craig-Hallum initiated coverage on Spire Global with a Buy rating and a $13 price target. Shares rose 1.1% to $9.33.
The Buy rating and price target from Craig-Hallum are likely to have a positive short-term impact on SPIR's stock price.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 100
POSITIVE IMPACT
Guggenheim initiated coverage on Twist Bioscience with a Buy rating and a $53 price target. Shares gained 6.8% to close at $46.98.
The Buy rating and significant price target from Guggenheim are likely to boost investor confidence, leading to a positive short-term impact on TWST's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100